PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway. - Wikidata - wikimedia - TriplyDB

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

http://www.wikidata.org/entity/Q37109666

about

High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer.Down-regulation of RPS9 Inhibits Osteosarcoma Cell Growth through Inactivation of MAPK Signaling Pathway Diagnostic investigations of PLA2G16 and CDH11 expression levels as independent prognostic markers of human osteosarcoma.PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.Nanotechnology in orthopedics: a clinically oriented review.

P2860

Q33639199-008D9B4C-93F2-4696-86FA-819488C885D9 Q41721808-33A59ADB-6530-4FD0-91A8-8F3BB7BC9261 Q47114856-C253F756-BC97-4C0F-BD63-6441E8655E12 Q49959181-F0CC9E8D-9BB5-433E-87C5-7C51F0AE4962 Q52676757-1A16660F-9402-48F1-8751-F7727959A2F4

P2860

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

http://www.wikidata.org/entity/Q37109666

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@en

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@nl

type

label

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@en

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@nl

prefLabel

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@en

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@nl

P1433

Q37109666-BDD36915-8314-41F7-8F8C-3AC3FCAAC1F3

P1476

Q37109666-F8F2F952-CD2D-4AA8-88F1-CBCCA76414FE

P2093

Q37109666-077580B8-6815-471B-B1C3-87F2F6A34747

Q37109666-403147BD-1C27-4E2D-9DFF-725419141818

Q37109666-5B1410A3-E2FC-4B3D-AD82-C2C85E84B257

Q37109666-61F7E625-98A1-4E69-B53F-896E2F7BFBC4

Q37109666-6F02AEEF-DD42-479E-947A-3BFB7ACB4171

Q37109666-75BC2166-E93D-4E83-ADE1-63002D6484AE

Q37109666-768D8317-92F5-4BC5-BFE7-A68B94BAA8F4

Q37109666-903E3995-92B7-4170-8008-EC7C7C57AFDE

Q37109666-90AAE05C-71BE-43E2-B3A8-ABF9B5757827

Q37109666-F78F6F96-BD83-4AE7-9914-721CDA6B9BFA

P2860

Q37109666-04A4ECF6-60D4-4AAA-BE85-215D83B3D329

Q37109666-09F14CA4-687C-4E6A-9B53-CC7A97A2DB23

Q37109666-0AFAE0B7-4229-4DBE-9EBE-12CB195252F0

Q37109666-1C416AB3-B9D1-404E-956D-FCB44A4CC8CB

Q37109666-1F3FCBCE-8883-4F4B-9FE3-C01FA78723C4

Q37109666-276C35A1-D719-46D6-ADE3-4B74A61E1AFA

Q37109666-2EABF8D4-4CCE-425B-B628-EEA3DB995EDB

Q37109666-3237C06D-1F08-4A73-B127-ADADB780BAC2

Q37109666-32FCAAEF-75DC-486B-A787-10E4DFFFEDA8

Q37109666-35703D49-0113-497A-ACE4-27CC52F20CCD

P304

Q37109666-5F73F9A3-D908-4F50-8C02-F36E9D60D786

P31

Q37109666-BAC8E1BD-5513-4C86-8B49-6F4A6A5EEE65

P356

Q37109666-A3A9F544-12D6-44E9-B682-9163D8D2AEAD

P407

Q37109666-BAEA3734-C0C4-40B0-9F87-4A0463447FB7

P433

Q37109666-312B1838-B5EE-49CA-87A8-8A84D831FAFF

P478

Q37109666-CA531458-CFB4-4417-952B-245C6B4CFC3B

P50

Q37109666-1D420440-D2B5-48DE-8AB6-56840FE5B144

P577

Q37109666-4FAEE95D-E223-4C35-8E3B-3E59427E6408

P698

Q37109666-22682902-41AD-4683-BCE8-9AB0BE33244B

P932

Q37109666-51FC7782-8BFB-4D8D-AB20-7D1AC2010ABC

P356

ONCOTARGET.7694

P1433

P1476

PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

@en

P2093

Bingzheng Zhou

http://www.w3.org/2001/XMLSchema#string

Guowen Wang

http://www.w3.org/2001/XMLSchema#string

Lin Li

http://www.w3.org/2001/XMLSchema#string

Luling Shan

http://www.w3.org/2001/XMLSchema#string

Shoulei Liang

http://www.w3.org/2001/XMLSchema#string

Shunbin Xiong

http://www.w3.org/2001/XMLSchema#string

Tianyang Mu

http://www.w3.org/2001/XMLSchema#string

Xiuxin Han

http://www.w3.org/2001/XMLSchema#string

Xueli Yang

http://www.w3.org/2001/XMLSchema#string

Yanqin Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling

Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells

AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency

Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA)

H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling

Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors

Regulation of peroxisomal lipid metabolism by catalytic activity of tumor suppressor H-rev107

New small molecules targeting apoptosis and cell viability in osteosarcoma

Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

P304

18021-18035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.7694

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Amanda R Wasylishen

P577

2016-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26933804

http://www.w3.org/2001/XMLSchema#string

P932

4951268

http://www.w3.org/2001/XMLSchema#string